Weight loss drug maker sinks 25% after new safety data spooks investors

Affected assets and topics

Expected market reaction

Evidence trail

Prediction lifecycle

• Rule-Based Analysis not AI MET Bearish 70% 6h
  Generated → 6h → Excluded

  Excluded: no stored price within tolerance of this prediction's maturity, checked by rescore_expired_predictions

Logged at publication, scored automatically once the window closes — never edited.

Original source

While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.

Read the full article on CNBC

Original article published by CNBC on June 8, 2026. Analysis and insights provided by AnalystMarkets AI.

More of the MET narrative

• 02:59 Xi Jinping meets foreign leaders: tracker, August 2026 South China Morning Post
• 21:50 Phemex puts 82 tokens on notice over liquidity and project compliance concerns CryptoSlate
• 21:30 India needs to make up its mind about economic ties with China South China Morning Post
• 19:56 John Galliano pulls out of Met Gala exhibit after antisemitism backlash South China Morning Post